Alnylam (ALNY) Stock
NSQ · ALNY
253.38
Fundamentals
Market cap
$34.25B
Price / Earnings ratio
41.3x
Price / Sales ratio
7.0x
Price / Book ratio
24.7x
Return on assets
12.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
NeutralALNYSeptember 21, 2026
Zacks Investment ResearchNeutral
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
ALNY

MarketBeat
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
NeutralALNYSeptember 20, 2026
MarketBeatNeutral
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
ALNY

MarketBeat
Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
NeutralALNYSeptember 20, 2026
MarketBeatNeutral
Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
ALNY

The Motley Fool
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
NeutralALNYSeptember 15, 2026
The Motley FoolNeutral
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
ALNY
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesBuy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral3
Buy12
Strong Buy1
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
4B3B1B0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
6B4B2B0
Revenue to Profit
2025$3.7B
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$313.7M
Net incomeEarnings
EPS forecast
Actual EPS
$0.32
$-0.16
Q2FY25
$2.90
$1.23
Q3FY25
$1.46
Q4FY25
$1.83
Q1FY26
$1.56
Q2FY26
The market is expecting earnings per share of $1.56 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
NeutralALNYSeptember 21, 2026
Zacks Investment ResearchNeutral
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
ALNY

MarketBeat
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
NeutralALNYSeptember 20, 2026
MarketBeatNeutral
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
ALNY

MarketBeat
Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
NeutralALNYSeptember 20, 2026
MarketBeatNeutral
Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
ALNY

The Motley Fool
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
NeutralALNYSeptember 15, 2026
The Motley FoolNeutral
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
ALNY

Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
NeutralALNYSeptember 2, 2026
Business WireNeutral
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
ALNY

Zacks Investment Research
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
NeutralALNYSeptember 1, 2026
Zacks Investment ResearchNeutral
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
ALNY

Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
NeutralALNYAugust 30, 2026
Business WireNeutral
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
ALNY

Stocktwits
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
NeutralALNYAugust 28, 2026
StocktwitsNeutral
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
ALNY

Business Wire
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
NeutralALNYAugust 24, 2026
Business WireNeutral
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
ALNY

Business Wire
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NeutralALNYAugust 20, 2026
Business WireNeutral
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
ALNY
About Alnylam
Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options.
SectorHealthcare
IndustryBiotechnology
Employees2,500
CEODr. Yvonne L. Greenstreet M.B.A., M.D.
IPO DateMay 28, 2004
HeadquartersCambridge, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Yvonne L. Greenstreet M.B.A., M.D. | CEO & Director | 1963 |
| Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board | 1945 |
| Mr. Jeffrey V. Poulton M.B.A. | CFO & Executive VP | 1968 |
| Mr. Bryan Andrew Supran J.D. | Chief Legal Officer | 1970 |
| Dr. Pushkal P. Garg M.D. | Executive VP & Chief Research & Development Officer | 1968 |
| Mr. Tolga Tanguler M.B.A. | Executive VP & Chief Commercialization Officer | 1973 |
| Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer | — |
| Dr. Kevin Joseph Fitzgerald Ph.D. | Executive VP, Chief Scientific Officer and Head of Early Research & Early Development | 1968 |
| Mr. Joshua Brodsky | Vice President of Investor Relations | — |
| Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer | — |
Fundamentals
Valuation
Market cap$34.25B
Price-to-sales ratio6.95
Price-to-book value24.66
Price-earnings ratio41.30
Return on Equity97.00%
Return on Sales21.00%
Return on Assets12.00%
PEG ratio0.46
Earnings Per Share
Earnings Per Share$6.10
Income Statement
Average volume1,571,212
EBITDA$939.73M
1 year high (52w)$495.55
1 year low (52w)$197.81
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesBuy12 Indicators
What the experts say
16 Wall Street Analyst Ratings
BUY
81% Buy
19% Hold
0% Sell
Target price
$356.19
Est return
39.11%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +6.4 | -17.2 | +10.5 | -5.8 | ||||||||
| 2022 | -20.9 | +8.9 | +0.5 | -21.2 | -9.5 | +18.5 | -4.2 | +47.7 | -5.2 | +5.3 | +3.5 | +7.9 |
| 2023 | -3.1 | -14.9 | +2.5 | -0.7 | -8.4 | +0.7 | +3.0 | +4.6 | -12.0 | -15.2 | +7.2 | +11.7 |
| 2024 | -11.3 | -13.6 | -2.1 | -6.1 | -1.0 | +61.5 | -2.4 | -2.2 | +8.4 | -3.4 | -7.6 | -7.0 |
| 2025 | +16.1 | -10.1 | +10.9 | +2.9 | +19.4 | +6.5 | +21.8 | +11.1 | +2.0 | -1.0 | +4.0 | -12.5 |
| 2026 | -15.5 | -1.8 | +1.8 | -5.9 | +2.0 | +1.8 | -31.9 | +9.2 | +4.0 |



